Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.

The Journal of clinical endocrinology and metabolism
Q1
Feb 2013
Citations:101
Influential Citations:10
Interventional (Human) Studies
82
S2 IconPDF Icon

Abstract

No abstract available